361 results about "Diabetic nephropathy" patented technology

The invention relates to the technical field of medical health big data analysis, in particular to a diabetic nephropathy risk identification method and system based on big data analysis, and the method comprises the following steps: screening key index features of risk patients through big data analysis based on health risk data of diabetic nephropathy patients; association of key indexes of the risk patients is analyzed, risk index interaction features are extracted, risk feature constraint conditions are determined, virtual sample parameters are identified through multi-dimensional data association, and a virtual sample set of the risk patients is established. According to the method, interaction characteristic values are extracted by analyzing key indexes of risk patients, high-risk index association is accurately captured, coverage and balance are enhanced based on multi-dimensional data association, non-stationary influence is solved by combining time sequence key change rate and shear point identification, and accurate matching is realized by analyzing offset rate and change trend. And the overall risk level is quantitatively evaluated by integrating interval data weighting, so that the risk identification comprehensiveness and the result reliability are improved.

The invention relates to the field of medical information processing and traditional Chinese medicine curative effect evaluation, in particular to a diabetic nephropathy traditional Chinese medicine curative effect evaluation method based on patient report outcome. The method comprises the following steps: searching related symptoms and clinical characterization data of diabetic nephropathy through a medical database, extracting target entries, performing language standardization processing, constructing an initial candidate entry set, calculating the occurrence frequency of each symptom entry, and screening entries meeting a set threshold value to form an entry set; carrying out dimension division on the entry set according to feature attributes to form a preliminary dimension structure set; forming a screening result set through preset logic screening conditions; and carrying out weighted regression fusion on the comprehensive curative effect score and clinical detection data, and outputting a patient curative effect index. In an item weight determination process, dynamic balance between subjective experience and objective statistical information is realized through a mixed weighting model, and the defects of strong subjectivity of expert scoring and large result fluctuation in a traditional method are overcome.

A class of compounds and the use thereof in a drug. Specifically, the present invention relates to a class of new compounds, a pharmaceutical composition containing the compounds, a method for preparing the compounds, and the use of the compounds or the pharmaceutical composition in the preparation of a drug for treating GLP-1 receptor agonist-mediated diseases and / or disorders, particularly the use in the preparation of a drug for treating diabetes, non-alcoholic fatty liver disease, obesity, myocardial infarction, heart failure, diabetic nephropathy, Parkinson's disease and Alzheimer's disease.

The invention discloses a diabetic nephropathy risk assessment and prediction system based on platelet indexes, and particularly relates to the technical field of disease risk prediction, which comprises a platelet index acquisition module, a drug use data acquisition module, a drug intervention assessment module, an index correction module, a clustering analysis module and a diabetic nephropathy risk assessment module, the method comprises the following steps: acquiring platelet related detection indexes and historical medication data of a patient, calculating a drug intervention influence index and generating a correction factor, realizing platelet index reverse reduction correction by adopting a convolutional neural network model, determining a similar group in combination with clustering analysis, and dynamically evaluating the risk of diabetic nephropathy based on the average morbidity of the group. Personalized accurate prediction is realized; the platelet index correction accuracy is improved, individualized drug intervention elimination is achieved, the similar population clustering analysis precision is enhanced, diabetic nephropathy risk prediction is dynamically adjusted in combination with comprehensive scores, and the early screening and individualized intervention effects are improved.

The invention provides a diabetic nephropathy early warning method, system, equipment and medium, and relates to the technical field of medical data analysis and prediction.The method comprises the steps that multiple urine samples of a user are collected, target urine protein detection is conducted, and multiple urine protein concentrations are obtained; each urine protein concentration is combined with a normal urine protein concentration set to be input into an abnormal data recognition tree, the number of layers of multiple recognition nodes is obtained, and the detection confidence coefficient is obtained through calculation; configuring an abnormal proportion according to the detection confidence coefficient, inputting a plurality of urine protein concentration combination normal urine protein concentration sets into an abnormal data identification tree, deleting urine protein concentrations divided into abnormal data in the abnormal proportion before, and obtaining screened urine protein concentrations; according to the screened urine protein concentration, an auxiliary early warning coefficient is obtained through calculation, and early warning is carried out. The technical problem of low early warning accuracy of diabetic nephropathy in the prior art is solved.

The invention relates to an application of a compound DB07268 in preparation of a RAGAP1 inhibitor. Candidate compounds possibly interacting with RACGAP1 protein are screened out through large-scale virtual docking and CCK8 experiments and verified through SPR experiments, the compound DB07268 with the highest affinity with RACGAP1 is further screened out, and finally the acting effect of the compound DB07268 is verified through cell experiments and molecular experiments. Compared with the prior art, the invention discovers that DB07268 can be used as the RACGAP1 inhibitor for targeted therapy of RACGAP1 related diseases, such as various tumors, diabetic nephropathy, acute kidney injury, congenital heart disease, congenital erythropoiesis abnormality anemia, virus infectious diseases and the like.

The invention discloses a traditional Chinese medicine extract composition for treating diabetic complications and a preparation method thereof, and belongs to the technical field of medicines. The traditional Chinese medicine extract composition is mainly prepared from the following raw material extracts: raw radix astragali, rhizoma anemarrhenae, rhizoma atractylodis, cortex phellodendri, radix trichosanthis, fructus corni, radix puerariae and ginseng leaves. The traditional Chinese medicine composition is used for treating diabetes mellitus and various complications thereof, including diabetes mellitus complicated with coronary heart disease, diabetes mellitus complicated with hypertension, diabetes mellitus complicated with cerebrovascular lesion, diabetic nephropathy, diabetic fundus lesion, diabetic peripheral neuropathy and the like, and has the advantages of remarkable clinical curative effect, no obvious side effect, low price, good comprehensive therapeutic property and the like.

The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.

The invention provides a method and device for predicting diabetic nephropathy, electronic equipment and a storage medium. The method comprises the following steps: acquiring questionnaire data of a target diabetic patient, and a first fundus image and a second fundus image of the same type; constructing a target Bayesian network according to the questionnaire data; based on the target Bayesian network, calculating joint probability distribution of the target diabetic patient concurrent diabetic nephropathy to obtain a first probability value; performing difference feature extraction on the first fundus image and the second fundus image to obtain target difference feature data; performing concurrent diabetic nephropathy probability prediction on the target difference feature data to obtain a second probability value; and according to the first probability value and the second probability value, determining a target probability of complicating diabetic nephropathy of the target diabetic patient. The invention aims to construct a simple, economic and low-trauma early screening system for diabetic nephropathy.

The invention relates to application of targeted intervention FBP2mRNA in preparation of a medicine for preventing and treating diabetic nephropathy, and belongs to the technical field of biomedicine. The invention provides an application of FBP2mRNA as a therapeutic target in preparation of a medicine for preventing and treating diabetic nephropathy. The NCBI (National Center of Biotechnology Information) login number of the FBP2mRNA is NM003837.4. The invention also provides an application of the shRNA for specifically interfering with the expression of the FBP2mRNA in the preparation of a medicine for preventing and treating diabetic nephropathy, wherein the nucleotide sequence of the shRNA is shown as SEQ ID NO. 1. It is found for the first time that targeted inhibition of the expression level of FBP2mRNA can effectively reduce the lipid level in mouse glomerular podocytes, reduce the expression level of lipid synthesis related genes and reduce the activity of lipid synthesis protein, and then the effect of treating diabetic nephropathy is achieved, so that FBP2mRNA can be used as a drug treatment target, and the treatment effect of diabetic nephropathy is improved. The application is applied to research, development and preparation of diabetic nephropathy prevention and treatment medicines.

The invention provides application of asperuloside in preparation of a medicine for treating diabetic nephropathy, the structural formula of the asperuloside is as shown in the specification, and imgabs0 #. Experiments find that the asperuloside has the effect of delaying the diabetic nephropathy of db / db mice, and a new method is provided for treating the diabetic nephropathy.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.

The invention discloses a machine learning-based diabetic nephropathy risk prediction system for type 1 diabetic patients, and is applied to the technical field of diabetic nephropathy risk prediction. Comprising a data processing module, a feature selection module, a machine learning module, a performance evaluation module and a model interpretation module. The data processing module collects and preprocesses data of a patient, the feature selection module selects optimal features based on a feature selection algorithm, the machine learning module constructs a machine learning model and performs prediction, and the performance evaluation module evaluates the performance of the machine learning model. And the model explanation module is used for explaining contributions of different features to a prediction result. According to the method, the DN risk of the T1DM patient can be accurately evaluated and predicted, the understanding of key features of the model is enhanced, and a clinician is helped to make a better decision when the severity of the disease is evaluated.

The present disclosure relates to peptide fragments derived from interleukin-4 (IL-4) for the treatment of diabetic nephropathy.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis, and chronic obstructive pulmonary disorder (COPD).

A tricyclic compound, and a preparation method therefor and the use thereof. Particularly, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof in the drugs for treating chronic kidney disease, kidney or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism, and Cushing syndrome, wherein the definition of each substituent in general formula (I) is the same as defined in the description.

The invention provides a traditional Chinese medicine composition for treating diabetic nephropathy and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition provided by the invention is prepared from the following raw materials in parts by weight: 30 to 120 parts of raw radix astragali seu hedysari, 10 to 20 parts of radix pseudostellariae, 5 to 15 parts of herba dendrobii, 5 to 15 parts of radix trichosanthis, 10 to 20 parts of radix rehmanniae recen, 10 to 20 parts of raw radix puerariae, 25 to 35 parts of herba agrimoniae, 5 to 15 parts of rhizoma discoreae, 10 to 20 parts of fructus corni, 10 to 20 parts of ramuli euonymi, 10 to 20 parts of serissa serissoide, 25 to 35 parts of chinaroot greenbrier, 4 to 8 parts of fructus schisandrae chinensis, 10 to 20 parts of herba pyrolae and 10 to 20 parts of corn stigma. The traditional Chinese medicine composition disclosed by the invention can be used for improving the clinical curative effect, improving symptoms, repairing podocyte damage and relieving oxidative stress by virtue of unique traditional Chinese medicine composition and aiming at pathogenesis treatment of the DN with the syndrome of deficiency of both qi and yin, and a new thought and a new method are provided for traditional Chinese medicine treatment of the DN.

The invention belongs to the technical field of medicines, and particularly relates to application of BMP9 as an intervention target in preparation of a medicine for treating diabetic nephropathy. More specifically, the invention provides application of a BMP9 accelerant in preparation of a medicine for preventing and / or treating diabetic nephropathy. The BMP9 accelerant is a substance shown in the following (i) or (ii): (i) a substance for increasing the content of BMP9 in a subject; (ii) a substance that increases BMP9 activity in a subject. According to the invention, a DKD mouse model is constructed, and liver RNA-seq sequencing is carried out, such that a differential expression gene BMP9 exists between a normal mouse and a DKD mouse. It is found that BMP9 can be used as a new target for prevention and treatment of DKD and has important theoretical significance and potential clinical application value.

The invention provides application of triptophenolide in preparation of a medicine for treating diabetic nephropathy, the structural formula of the triptophenolide is as shown in the specification, and # imgabs0 #. Experiments find that the triptophenolide has the effect of delaying the diabetic nephropathy of db / db mice, and a new method is provided for treating the diabetic nephropathy.

The invention relates to the technical field of image processing, in particular to a tongue picture auxiliary identification method and system for a diabetic nephropathy patient and a medium. The method comprises the steps of obtaining tongue picture region images, clustering the tongue picture region images based on preset different numbers of clustering clusters, and screening an optimal clustering result according to a clustering result; obtaining the attribution degree of each pixel point in each cluster in the optimal clustering result by combining the gray scale gradient rule of the pixel points in different directions in the neighborhood of each pixel point and the relative position relationship between the pixel points and each cluster in the optimal clustering result; according to the difference of the attribution degrees of each pixel point and the neighborhood pixel points thereof in the same cluster in the optimal clustering result, acquiring the attribution expression degree of each pixel point and each cluster in the optimal clustering result; and according to the affiliation representation degree and the initial membership degree of each pixel point and each cluster in the optimal clustering result, the tongue picture region image is divided again. According to the invention, the accuracy of the tongue picture region image division result is improved.

The invention belongs to the technical field of biological medicine, and particularly relates to application of CNPY2 as a new target in diagnosis and treatment of diabetic nephropathy. The invention provides a biomarker CNPY2 gene or CNPY2 protein for auxiliary diagnosis of diabetic nephropathy for the first time. The expression of the CNPY2 in the renal tubule of a DN patient is up-regulated, the expression of the CNPY2 in the renal tubule of a db / db mouse is up-regulated, and the expression of the CNPY2 in an HK-2 cell subjected to in-vitro high-glucose culture is up-regulated; therefore, the CNPY2 can be used as an auxiliary diagnosis index of the diabetic nephropathy for auxiliary diagnosis of the diabetic nephropathy. The invention also provides a kit for auxiliary diagnosis of diabetic nephropathy. The kit contains a detection reagent of the CNPY2 gene or the coded protein. The invention also finds that by knocking down the adeno-associated virus through the CNPY2 and inhibiting the expression or activity of the CNPY2 through the specific small interfering RNA of the adeno-associated virus, the pathological injury of the renal tubules of db / db mice can be obviously improved, the integrity of MAM in the renal tubule epithelial cells is improved, and the ferroptosis, ERS and mitochondrial injury of the renal tubule epithelial cells are alleviated; therefore, the CNPY2 can be used as a drug, a drug target or a target gene in gene therapy, and is applied to prevention, alleviation or / and treatment of diabetic nephropathy.

The invention discloses a rapid detection device for diabetic nephropathy patients, and belongs to the technical field of diabetic nephropathy patient detection.The rapid detection device comprises a blood glucose detection assembly, a self-adaptive adjusting mechanism, an extrusion force adjusting structure and an automatic blood taking mechanism, and the self-adaptive adjusting mechanism is arranged on the blood glucose detection assembly; the extrusion force adjusting structure is arranged in the blood glucose detection assembly, the extrusion force adjusting structure is connected with the self-adaptive adjusting mechanism, the extrusion force adjusting structure comprises an adjusting assembly and a reciprocating displacement assembly, and the automatic blood taking mechanism is arranged on the blood glucose detection assembly. By arranging the self-adaptive adjusting mechanism, the extrusion force adjusting structure and the automatic blood taking structure, the extrusion force for assisting the blood taking structure of the person to be detected is self-adaptively adjusted according to different thicknesses of the hands of the person to be detected, and it is ensured that the device can take out sufficient blood for detection; and tissue fluid groups which influence a detection result can be prevented from existing in blood, so that the detection precision of the device is improved.

The invention relates to the technical field of medical artificial intelligence diagnosis, and discloses a diabetic nephropathy auxiliary identification method based on multi-source data. The method comprises the following steps: starting a medical data traceability process, capturing original indexes from a multi-heterogeneous system, and arranging the original indexes into an initial data set; and performing hierarchical data fusion according to the pathological evolution knowledge graph to generate a fusion health record with a timestamp. And introducing a dynamic feature weaving process, and extracting a multi-level abnormal feature network from the physiological parameter trajectory according to the priority of the biomarker. And importing the abnormal feature network into a progressive mode learning process, training an identification engine for mapping feature combinations to different disease risk levels, and outputting an identification conclusion by the engine. According to the method, the structured abnormal mode network is constructed through priority-driven dynamic feature weaving, and the recognition engine is trained by using a progressive learning mechanism, so that the accuracy and clinical interpretability of risk stratification of diabetic nephropathy are improved.

The invention relates to the technical field of biological medicine, and discloses an application of an Aspisin small-molecule inhibitor in preparation of a medicine for preventing and / or treating diabetic nephropathy, and the Aspisin small-molecule inhibitor comprises ganoderic acid DM. The inhibitor ganoderic acid DM targeting Aspisin is screened from a bioactive compound library by combining high-throughput virtual drug screening with biological activity screening, it is found that ganoderic acid DM can be specifically combined with Aspisin and shows high affinity, and it is expected that an experimental basis is provided for clinical treatment and prevention of DKD and new drug research and development.

The invention relates to a non-invasive diabetic nephropathy grading and predicting method supporting convenient screening, which comprises the following steps: acquiring and preprocessing a color fundus image and non-invasive clinical features of a diabetic patient to obtain a multi-modal data set, and setting marks of various severity degrees of diabetic nephropathy; constructing a deep learning model A1, and obtaining diabetic nephropathy severity prediction probability distribution # imgabs0 # based on the color fundus image according to the multi-modal data set; a deep learning model A2 is constructed, and diabetic nephropathy severity prediction probability distribution # imgabs1 # based on clinical data is obtained according to the multi-modal data set; and constructing a fusion model, fusing the obtained diabetic nephropathy prediction probabilities by the fusion model through a self-adaptive weight distribution algorithm, dynamically adjusting the weight according to the prediction result output by each model, calculating a comprehensive diabetic nephropathy severity score, and outputting a final diabetic nephropathy prediction grading result according to the score.

The invention provides a kidney prognosis risk prediction method and system for a patient diagnosed as type 2 diabetic nephropathy through pathology, and relates to the technical field of prognosis risk prediction.The method comprises the steps that clinical data of the T2DN patient meeting the screening standard are obtained; screening the clinical data through an LASSO regression method so as to screen out key clinical indexes related to kidney prognosis; based on the key clinical indexes, constructing a risk prediction model by using a Cox proportional risk model; performing performance analysis on the risk prediction model by using clinical data of the training queue and the verification queue, and performing internal verification on the risk prediction model by using a Bootstrap method to ensure the robustness and reliability of the model; and inputting clinical data of a to-be-tested patient into the risk prediction model to obtain a prediction result. By screening key clinical indexes, an individualized risk prediction model is constructed, and a scientific basis is provided for clinical early intervention.

The present invention discloses a polypeptide compound and its application in preventing or treating diabetes or diabetic complications. The polypeptide compound shows good long-term hypoglycemic effect and therapeutic effect of diabetic nephropathy; at the same time, it has the effects of high enzymatic stability, high biological activity, no adverse reactions, etc., and can be used to prepare drugs for treating overeating, obesity and overweight, elevated cholesterol, diabetes and diabetic nephropathy.

The present invention discloses phenyl-substituted dihydronaphthyridine compounds a preparation therefor and a use thereof, and belongs to the technical field of medicine. The compounds disclosed in the present invention are represented by formula I, and can be used as a mineralocorticoid receptor antagonist for treating, preventing or alleviating aldosteronism hyperplasia, diabetic nephropathy, hypertension, heart failure (comprising chronic heart failure, etc.), sequelae of myocardial infarction, liver cirrhosis, renal failure, stroke and other diseases in patients.

The invention relates to the technical field of molecular biology, in particular to a methylation marker for diagnosis of diabetic nephropathy. Specifically, the methylation marker comprises a P site of a CAT gene promoter region and / or an E site of a CAT gene exon 1 region. Based on a detection system combining methylation sensitive restriction enzyme with quantitative PCR, the kit has the advantages of simplicity and convenience in operation, good repeatability, accuracy in quantification and easiness in standardization, and is suitable for low-invasive samples such as peripheral blood. By effectively distinguishing pure type 2 diabetes patients from diabetic nephropathy combined patients, a reliable technical means is provided for risk stratification, early intervention and dynamic monitoring of diabetic people, and the method has good clinical application prospects and popularization value.

The present invention relates to a pyridine polycyclic compound inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound, and a use of the compound in a medication for treating chronic kidney disease, kidney or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism, and Cushing syndrome, wherein the definitions of the substituents in formula (I) are the same as those in the description.